3Sadao Kamidoro,Akira Fajiio,Masuyoshi Harada,et al.Fundamental and clinical studies on S6472 in the urological field[J].Jap .J.of antibiotics,1985,38(3):869-904.
4大泉耕太郎 斋藤玲 渡边彰 等.Long—acting preparation of celaelor（S6472）—pharmacokinetics and clinical evaluation to the pationts with respiration trail Infection[J].最新医学,1985,40(8):1747-1757.
5Forrest A,NIX DE.,Ballow C H,et al.Pharmacodynamis of intravenous ciprofxacin in seriously ill patient[J].Antimicibial Against and chemother,1993,37(5)1073-1081.
6Lacy M K,Wen lu,Xiao wei Xu,et al.Pharmacodynamic Comparisous of Levofloxacin,Ciprofloxacin,and Ampicillin against Streptococcus pneumoniae in an In vetio Model of infection[J].Antimicrobial Agents chemother,1999,43(3):672-677.
7SchentagJ.J.Clinical pharmacology of the Fluoroquinolone:studies in human Dynamie /Kinetic models[J].Clinical Infectons Disease,2000,31 (suppler 2):S40-4.
8Preston S L,Drusano G L,Berman AL.,A New paradigm for Early clinical Trials[J].JAMA,1998,279(2):125-129.
9Thomas J.k,Forrest A,Bhavnani S M.et al.Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy [J].Antimicrobial agents chemother,1998,42(3):521-527.
10Hooper D.C Mechanism of action and resistance of older and newer fluoroquinolons [J].Clinical Infectious Disease,2000,31(suppl.2)S24-8.
